Endpoints for radiofrequency ablation in Barrett's dysplasia

Area of Science:

• Gastroenterology
• Endoscopic therapeutics
• Barrett's esophagus research

Background:

• Esophageal adenocarcinoma incidence and prognosis necessitate advanced endoscopic treatments for Barrett's esophagus (BE).
• Radiofrequency ablation (RFA) is a recognized safe and effective endoscopic treatment for dysplastic BE.
• Previous studies on RFA durability had limitations in sample size, follow-up, and patient cohorts.

Discussion:

• Orman and colleagues report a 5.2% annual recurrence rate for dysplastic BE after RFA in a single-center retrospective study.
• No clinical factors, including segment length or dysplasia grade, were associated with BE recurrence post-RFA.
• Defining complete eradication (CE-D) after one negative endoscopic exam is debated; prior studies require a minimum of two.

Key Insights:

• RFA demonstrates durable efficacy in eradicating dysplastic BE.
• Low recurrence rates suggest RFA's potential for long-term disease management.
• Current surveillance protocols may need refinement based on RFA outcomes.

Outlook:

• Limitations include potential sampling errors in biopsies and significant patient attrition during surveillance.
• Multicenter, prospective studies are essential for establishing definitive post-RFA surveillance cessation guidelines.
• Identifying patients at higher risk for recurrence or progression post-RFA is a critical future research direction.